<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="896">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05149495</url>
  </required_header>
  <id_info>
    <org_study_id>8409</org_study_id>
    <nct_id>NCT05149495</nct_id>
  </id_info>
  <brief_title>Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery</brief_title>
  <acronym>STOP-SST</acronym>
  <official_title>Maintenance of Remission After Discontinuation of Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present there are no recommendations regarding the possibility of discontinuing treatment&#xD;
      in cases of recurrent acromegaly with good hormonal control. Discontinuation of treatment is&#xD;
      therefore most often decided by the practitioner, on the basis of his experience and&#xD;
      knowledge of the patient, the long-term course with somatostatin analogues being very little&#xD;
      described.&#xD;
&#xD;
      Thus, although hormonal control is achieved in a majority of cases under medical treatment,&#xD;
      we do not know if it is possible to stop treatment and in this case how the pathology&#xD;
      evolves. It would appear that approximately 40% of patients defined as very good responders&#xD;
      to somatostatin analogues may gradually space their injections.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">March 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Study of the clinical and biological evolution, after discontinuation of treatment with somatostatin analogues, of acromegalic patients with recurrence after surgery.</measure>
    <time_frame>Files analysed retrospectively from January 01, 2000 to September 01, 2021 will be examined]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acromegaly</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subject operated for a pituitary adenoma at the HUS between 01/01/2000 to 09/01/2021&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Major subject (≥18 years old)&#xD;
&#xD;
          -  Having been seen at least once in consultation in the Internal Medicine, Endocrinology&#xD;
             and Nutrition department of Hautepierre Hospital&#xD;
&#xD;
          -  Subject operated for a pituitary adenoma at the HUS between 01/01/2000 to 09/01/2021&#xD;
&#xD;
          -  In whom biological confirmation of recurrence has been demonstrated&#xD;
&#xD;
          -  Patient not having expressed his opposition, after information, to the reuse of his&#xD;
             data for scientific research purposes.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Subject having expressed opposition to participating in the study&#xD;
&#xD;
          -  Treatment pre and / or post surgery by radiotherapy&#xD;
&#xD;
          -  No recurrence&#xD;
&#xD;
          -  No treatment with a somatostatin analogue for recurrence&#xD;
&#xD;
          -  Subject under guardianship, curatorship or safeguard of justice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe BALTZINGER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service Médecine Interne, Endocrinologie et Nutrition - Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe BALTZINGER, MD</last_name>
    <phone>33 3 88 12 75 82</phone>
    <email>philippe.baltzinger@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service Médecine Interne, Endocrinologie et Nutrition - Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe BALTZINGER, MD</last_name>
      <phone>33 3 88 12 75 82</phone>
      <email>philippe.baltzinger@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Philippe BALTZINGER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ninon STAHL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acromegaly</keyword>
  <keyword>Pituitary microadenoma</keyword>
  <keyword>Pituitary macroadenoma</keyword>
  <keyword>Somatostatin analogues</keyword>
  <keyword>Hormonal control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Acromegaly</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

